A groundbreaking study conducted by researchers at the University of Victoria has unveiled a compelling trend among survivors of traumatic brain injury (TBI) who are turning to psychedelics as a form of self-medication. This pioneering investigation reflects an urgent shift in the exploration of alternative treatments for TBI symptoms that have traditionally been difficult to manage through conventional medical approaches. For the first time, clinical psychology experts have meticulously analyzed data from over 6,100 participants in the global psychedelic survey, revealing that a notable subset—nearly 1,200 individuals—employ psychedelics to alleviate various physical health conditions. Remarkably, 208 of these respondents specifically reported using these substances to cope with symptoms directly related to brain injuries, representing approximately 3.4 percent of the total survey cohort.
The study, published in the esteemed journal Progress in Neuropsychopharmacology & Biological Psychiatry, was led by University of Victoria doctoral candidate Baeleigh VanderZwaag, with senior guidance from clinical psychology professors Jill Robinson and Mauricio Garcia-Barrera. The research opens new windows into the intersection of neuropharmacology and trauma-related cognitive disorders, highlighting the possible neuroprotective and reparative properties of psychedelics. Twenty-first-century brain injury care has long grappled with the heterogeneous nature of TBI-related symptomatology, which encompasses cognitive deficits, mood disturbances, and persistent somatic complaints such as chronic headaches and migraines. Given the absence of universally effective treatments, the UVic team’s findings spotlight a growing movement among survivors seeking alternative therapeutic avenues.
Globally, it is estimated that around 60 million individuals suffer traumatic brain injuries each year. This staggering prevalence underscores the necessity for innovative treatment strategies that can address the multifaceted sequelae of TBI. Mauricio Garcia-Barrera emphasizes that no singular approach suffices for managing the complex spectrum of effects following brain trauma. The increasing utilization of psychedelics in this context suggests a paradigm shift, highlighting a growing public and clinical interest in compounds previously relegated to experimental or recreational use. These substances, often classified as hallucinogens, have been postulated to influence neuroplasticity and mood regulation significantly, making them candidates for novel neuropsychopharmacological interventions.
VanderZwaag and her team point out that despite the surging anecdotal evidence of psychedelic use among TBI survivors, empirical data derived from human participants remain scarce. Existing knowledge primarily stems from animal models, which, despite their value, cannot fully replicate the complexity of human brain injury or the subjective experience of symptom relief. This new research uniquely captures self-reported experiences, documenting patterns of use, dosage variations, and perceived efficacy. The revelation that individuals are independently sourcing these substances and experimenting outside clinical settings illuminates an urgent need for structured research protocols and potential clinical trials.
The findings reveal that psilocybin, a naturally occurring psychedelic compound, is the most frequently used agent among TBI respondents. These individuals typically engage in dosing cycles ranging from every two to five months to semiannual administration, employing both microdosing techniques and higher-dose sessions. Alongside psilocybin, substances such as LSD and ketamine also featured prominently in self-medication practices. This diverse compound usage reflects varied therapeutic goals and personal tolerance levels. The neuropharmacological mechanisms by which psychedelics might confer symptomatic relief include modulation of serotonergic systems, enhancement of synaptic connectivity, and attenuation of neuroinflammation — all crucial factors in brain injury recovery trajectories.
Of particular note, approximately 90 percent of respondents reported some degree of symptom improvement following psychedelic use. Symptoms most commonly mitigated included mood instability, cognitive impairments like memory and attention deficits, and somatic issues, particularly chronic headaches. Such subjective improvements are both intriguing and encouraging, suggesting that psychedelics may hold potential as adjunctive therapies within neurorehabilitation paradigms. Nonetheless, VanderZwaag cautions that while these preliminary results are promising, rigorous scientific evaluation is essential to assess safety profiles, dosage optimization, and long-term neuropsychological outcomes.
The research underscores significant gaps in current clinical understanding, particularly concerning the safety of psychedelics when used by individuals with a history of brain trauma. Since TBIs often involve disrupted neural circuits and heightened vulnerability to neurochemical imbalances, unsupervised psychedelic use could pose risks not yet fully elucidated. Furthermore, the heterogeneity of TBI—ranging from mild concussions to severe brain lesions—necessitates nuanced investigation to determine which subgroups may benefit most from psychedelic interventions. This area of inquiry aligns closely with the emerging field of psychopharmacology, which aims to tailor psychiatric and neurological treatments to individual biological and clinical profiles.
Looking ahead, VanderZwaag and collaborators plan to expand their analysis with data from the 2025 Global Psychedelic Survey, a more comprehensive and culturally diverse dataset translated into 18 languages. This forthcoming phase aims to enhance the representativeness of findings and explore cross-cultural variations in psychedelic use for brain injury symptoms. The large-scale nature of the survey permits exploration of broader psychosocial factors influencing medical self-experimentation, including access to healthcare, stigma around mental health treatment, and regional drug policy landscapes. Through such research, the team hopes to inform evidence-based guidelines and promote safe, informed therapeutic exploration.
With the increasing momentum surrounding psychedelic research in neuropsychiatry, this study situates traumatic brain injury within the broader context of neuroprotection and mental health innovation. It invites a reevaluation of how clinicians approach symptom management in TBI survivors, acknowledging the complex interplay between brain physiology, psychological wellbeing, and emerging pharmacotherapies. As healthcare systems grapple with the limitations of conventional treatments, the UVic study encourages integration of patient experiences with scientific rigor—a crucial step toward personalized brain injury care.
The University of Victoria distinguishes itself as an epicenter of transformative research and education, consistently producing collaborative and internationally impactful scientific work. Through initiatives like this, UVic exemplifies the pursuit of knowledge that transcends traditional disciplinary boundaries to address urgent global health challenges. By fostering interdisciplinary inquiry, from clinical psychology to neuropharmacology, UVic researchers forge pathways toward innovative therapies that may redefine neurorehabilitation and improve quality of life for millions worldwide.
In conclusion, this first-of-its-kind study acts as both a beacon and a cautionary tale within the burgeoning field of psychedelic medicine. The promising self-reported efficacy of psychedelics in managing TBI symptoms demands accelerated but carefully controlled scientific inquiry. Balancing potential benefits against unknown risks requires multi-phase clinical trials, nuanced neurobiological investigation, and a commitment to patient safety. Meanwhile, this research compels the medical community to listen attentively to the lived experiences of survivors, whose experimental journeys could ultimately pave the way for breakthroughs in brain injury treatment.
Subject of Research: People
Article Title: Psychedelics for the management of symptoms of traumatic brain injury: Findings from the global psychedelic survey
News Publication Date: 20-Mar-2026
Web References:
https://pubmed.ncbi.nlm.nih.gov/41621525/
http://dx.doi.org/10.1016/j.pnpbp.2026.111624
https://www.uvic.ca/news
References:
Progress in Neuropsychopharmacology & Biological Psychiatry, 2026
Image Credits: University of Victoria
Keywords: Brain injuries, Neuropharmacology, Psychopharmacology, Psychiatry, Psychotherapy, Alternative medicine, Neuroprotection, Mental health, Traumatic injury, Head concussions, Migraines, Pain
